About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker; Dr. Diana Rafael, main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) VHIR
Abstract: The constant development of new synthetic drug delivery systems in the last years have been highly contributing to the advancement of new treatments for a wide-range of challenging diseases, for which the conventional treatments are not efficient. The use of nanoparticles and hydrogels have been a breakthrough in clinical application, with hundreds of new products enrolling clinical trials and being approved in the clinical practice. In the CB-DDT group we are experts in the development of new therapeutic strategies based on nanoparticles and hydrogels for several different clinical applications. This presentation will be divided in two parts: The first one dedicated to the most promising works regarding the development of nanoparticles encapsulating different drugs and biomolecules for the systemic treatment of different pathological conditions, and the second one dedicated to the most promising results regarding the use of biodegradable, smart hydrogels for cancer local treatment.
Bio Sketch: Diana Rafael, is a Principal Investigator at VHIR. She has a PhD in Pharmaceutical Technology (2017), and since 2013 she has been associated with the Clinical Biochemistry: Drug Delivery and Therapy Group from VHIR, where she initiated a research line dedicated to the production and characterization of Delivery Systems. Diana participated in more than 12 highly competitive national and international research projects and her research work originated 2 patents and more than 40 peer-reviewed publications. This year, Diana was granted with a Global Marie Sk³odowska-Curie Postdoctoral Fellowship and a Grant from the Spanish Association against the Pancreatic Cancer. Moreover, since January Diana has been implementing a new section within the FVPR/U20 platform of the Nanbiosis, certified by ISO9001:2015, dedicated to the synthesis and characterization of Nanosystems.
Host: Dr. Ibane Abasolo, head of group Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) VHIR
